ReviewInternational journal of molecular sciences2023
Assessment of Apolipoprotein(a) Isoform Size Using Phenotypic and Genotypic Methods.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 15 citations in OpenAlex.
- Surface-enhanced Raman scattering spectroscopy of human cerebrospinal fluid: protocol selection and biomolecular interpretation.Analytical and bioanalytical chemistry · 2026Article
- Lipopotrein(a): from the complex metabolism to the optimal lowering drug.Internal and emergency medicine · 2026Review
- Lipoprotein(a) in Essential Hypertension: Associations with Blood Pressure and Hypertension-Mediated Organ Damage.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026Observational
- Lipoprotein(a) and Cardiovascular Disease: From Genetic Risk Factor to Therapeutic Target.Cells · 2026Review
- Association between lipoprotein(a) and atherosclerosis with different diabetic status: a cross-sectional study in a Chinese population.Cardiovascular diagnosis and therapy · 2025Article
- Genome analysis of a newly isolated Lysinibacillus fusiformis-YC01 for biodegrading inosine and guanosine.Biodegradation · 2025Article
- The functions of apolipoproteins and lipoproteins in health and disease.Molecular biomedicine · 2024Review
- Advantages of using Genetically Elevated Lipoprotein(a) Levels in Predicting 5-Year Major Adverse Cardiovascular Events Relating to Coronary Artery Disease in Women.Reviews in cardiovascular medicine · 2024Article
- Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?International journal of molecular sciences · 2024Review
- Lifestyle and Lipoprotein(a) Levels: Does a Specific Counseling Make Sense?Journal of clinical medicine · 2024Review
- Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels.Archives of medical science : AMS · 2024Article
- Predictive value of CA-153, CA-125 and Apo A for ocular metastasis in menopausal female patients with breast cancer.International journal of ophthalmology · 2024Article
- Estimating the Prevalence and Characteristics of Patients Potentially Eligible for Lipoprotein(a)-Lowering Therapies in a Real-World Setting.Biomedicines · 2023Article
- Sex X Time Interactions in Lp(a) and LDL-C Response to Evolocumab.Biomedicines · 2023Article
- Cardiac Sarcoidosis: A Contemporary Concept of Forgotten Granulomatosis.ARYA atherosclerosisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Apolipoprotein(a) (apo(a)) is the protein component that defines lipoprotein(a) (Lp(a)) particles and is encoded by the LPA gene. The apo(a) is extremely heterogeneous in size due to the copy number variations in the kringle-IV type 2 (KIV2) domains. In this review, we aim to discuss the role of genetics in establishing Lp(a) as a risk factor for coronary heart disease (CHD) by examining a series of molecular biology techniques aimed at identifying the best strategy for a possible application in clinical research and practice, according to the current gold standard.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.